DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/sgm63j/amitiza) has announced the addition of the "Amitiza (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023" report to their offering.
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Amitiza (lubiprostone) is indicated for the treatment of IBS-C in women 18 years of age and older, but only in the US. This product was developed by Sucampo Pharmaceuticals and Takeda, and initially gained approval in the US in 2006 for the treatment of chronic idiopathic constipation (CIC) in adults. In 2008, Amitiza gained a label expansion from the Food and Drug Administration (FDA) for the treatment of IBS-C in women of 18 years of age and older.
Scope
- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Amitiza including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Amitiza for the top 2 countries from 2013 to 2023.
- Sales information covered for the US and Japan.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Amitiza (lubiprostone)
7 Appendix
For more information visit http://www.researchandmarkets.com/research/sgm63j/amitiza
